These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 32157329)

  • 1. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases.
    Huang Q; Liu Q; Yin T; Hu L; Ding H; Liu S; Jiang Y
    Eur J Clin Pharmacol; 2020 Jun; 76(6):833-842. PubMed ID: 32157329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo.
    Yan M; Wu ZF; Tang D; Wang F; Xiao YW; Xu P; Zhang BK; Liu YP; Xiang DX; Banh HL
    Biomed Pharmacother; 2018 Dec; 108():60-64. PubMed ID: 30216801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine.
    Kuzin M; Schoretsanitis G; Haen E; Stegmann B; Hiemke C; Gründer G; Paulzen M
    Clin Pharmacokinet; 2018 Jun; 57(6):729-737. PubMed ID: 28866861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations.
    Blanco Dorado S; Maroñas Amigo O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Br J Clin Pharmacol; 2020 Aug; 86(8):1661-1666. PubMed ID: 32110830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
    Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
    Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
    Meyer UA
    Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
    Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
    Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of proton pump inhibitors in children.
    Litalien C; Théorêt Y; Faure C
    Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro study of the variable effects of proton pump inhibitors on voriconazole.
    Niece KL; Boyd NK; Akers KS
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5548-54. PubMed ID: 26124167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole.
    Qi F; Zhu L; Li N; Ge T; Xu G; Liao S
    Int J Antimicrob Agents; 2017 Apr; 49(4):403-409. PubMed ID: 28159656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole.
    Mafuru M; Wu S; Mayala H; Msengwa Z; Phillip A; Mgone C
    Pharmgenomics Pers Med; 2021; 14():1379-1389. PubMed ID: 34754219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
    Kita T; Sakaeda T; Baba T; Aoyama N; Kakumoto M; Kurimoto Y; Kawahara Y; Okamura N; Kirita S; Kasuga M; Okumura K
    Biol Pharm Bull; 2003 Mar; 26(3):386-90. PubMed ID: 12612455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
    Abed MN; Alassaf FA; Jasim MHM; Alfahad M; Qazzaz ME
    Pharmacology; 2020; 105(11-12):645-651. PubMed ID: 32289807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voriconazole-Induced Hepatitis via Simvastatin- and Lansoprazole-Mediated Drug Interactions: A Case Report and Review of the Literature.
    Lopez JL; Tayek JA
    Drug Metab Dispos; 2016 Jan; 44(1):124-6. PubMed ID: 26502771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update.
    Wedemeyer RS; Blume H
    Drug Saf; 2014 Apr; 37(4):201-11. PubMed ID: 24550106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
    Andersson T
    Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Impact of Co-medication of Levetiracetam and Clobazam with Proton Pump Inhibitors: A Drug Interaction Study.
    Pasupuleti B; Gone V; Baddam R; Venisetty RK; Prasad OP
    Curr Drug Metab; 2020; 21(2):126-131. PubMed ID: 32067615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of monoglyceride lipase by proton pump inhibitors: investigation using docking and in vitro experiments.
    Dahabiyeh LA; Abu-Rish EY; Taha MO
    Pharmacol Rep; 2020 Apr; 72(2):435-442. PubMed ID: 32048247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.